BMT CTN 1302- Multicenter Phase II, Double Blinded, Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma

Grant

Date/time Interval

  • April 21, 2017 - April 20, 2019

    • Awarded By

    Total Award Amount

  • 28636.00

    • Direct Costs

  • 19284.00

    • Sponsor Award Id

  • 10022

    • Contributor

  • Bhatia M.D., Ravi   Investigator  
  • Costa M.D., Ph.D., Luciano   Investigator  
  • De Idiaquez Bakula, Lorena   Investigator  
  • Di Stasi M.D., Antonio   Investigator  
  • Godby M.D., Kelly   Investigator  
  • Innis-Shelton M.D., Racquel   Principal Investigator  
  • Salzman M.D., Donna   Investigator